Yanfeng Zhao1, Xiqin Yang2, Xuhui Zhang2, Qin Yu3, Ping Zhao3, Jianxia Wang2, Cuimi Duan2, Jiangxue Li2, Heather Johnson4, Xiaoyan Feng5, Heqiu Zhang6. 1. Department of Bio-diagnosis, Institute of Basic Medical Sciences, 27, Taiping Road, Beijing, 100850, China; Beijing Research Institute for Tuberculosis Control, No 5, Dongguang Hutong, Xinjiekou, Beijing, 100035, China. 2. Department of Bio-diagnosis, Institute of Basic Medical Sciences, 27, Taiping Road, Beijing, 100850, China. 3. Chaoyang District Center for Disease Control and Prevention, 25 Panjiayuan, Huaweili, Beijing, 100029, China. 4. Olympia Diagnostics, Inc., Sunnyvale, CA 94086, USA. 5. Department of Bio-diagnosis, Institute of Basic Medical Sciences, 27, Taiping Road, Beijing, 100850, China. Electronic address: xyfeng2002@126.com. 6. Department of Bio-diagnosis, Institute of Basic Medical Sciences, 27, Taiping Road, Beijing, 100850, China. Electronic address: zhangheqiu2004@126.com.
Abstract
OBJECTIVE: We aimed to determine whether IP-10 and RANTES plasma levels can be used in diagnosis and monitoring of pulmonary tuberculosis (PTB). METHODS: Plasma levels of cytokines/chemokines were measured using a Bio-Plex® multiplex cytokine assay system in a cohort containing 457 clinically suspected PTB patients including a training set (n = 41)and two independent test sets A (n = 242) and B (n = 174). RESULTS: Plasma levels of IP-10 and RANTES were significantly higher in PTB patients than healthy controls' in both training and independent test sets (P < 0.05). Compared with other combinations, the combination of IP-10 and RANTES had the best performance with an AUC of 1.0 in training set. The performance characteristic of this model was successfully validated in independent test set A although this combination only resulted in a slightly improvement of AUC value in independent test set B. Plasma IP-10 and RANTES levels were weakly and positively correlated with blood glucose concentrations. Moreover, IP-10 levels were positively correlated with CRP and ESR in PTB patients. Furthermore, in response to therapy, both IP-10 and RANTES levels significantly decreased over the period of 6 months (P < 0.001). CONCLUSIONS: Taken together, combination of IP-10 and RANTES could be potentially used as diagnostic and monitoring biomarker in PTB management.
OBJECTIVE: We aimed to determine whether IP-10 and RANTES plasma levels can be used in diagnosis and monitoring of pulmonary tuberculosis (PTB). METHODS: Plasma levels of cytokines/chemokines were measured using a Bio-Plex® multiplex cytokine assay system in a cohort containing 457 clinically suspected PTB patients including a training set (n = 41)and two independent test sets A (n = 242) and B (n = 174). RESULTS: Plasma levels of IP-10 and RANTES were significantly higher in PTB patients than healthy controls' in both training and independent test sets (P < 0.05). Compared with other combinations, the combination of IP-10 and RANTES had the best performance with an AUC of 1.0 in training set. The performance characteristic of this model was successfully validated in independent test set A although this combination only resulted in a slightly improvement of AUC value in independent test set B. Plasma IP-10 and RANTES levels were weakly and positively correlated with blood glucose concentrations. Moreover, IP-10 levels were positively correlated with CRP and ESR in PTB patients. Furthermore, in response to therapy, both IP-10 and RANTES levels significantly decreased over the period of 6 months (P < 0.001). CONCLUSIONS: Taken together, combination of IP-10 and RANTES could be potentially used as diagnostic and monitoring biomarker in PTB management.
Authors: Ji Young Hong; Ahreum Kim; So Yeong Park; Sang-Nae Cho; Hazel M Dockrell; Yun-Gyoung Hur Journal: Front Cell Infect Microbiol Date: 2021-03-18 Impact factor: 5.293
Authors: Bih H Chendi; Candice I Snyders; Kristian Tonby; Synne Jenum; Martin Kidd; Gerhard Walzl; Novel N Chegou; Anne M Dyrhol-Riise Journal: Front Immunol Date: 2021-02-24 Impact factor: 7.561
Authors: Xia Qiu; Tao Xiong; Xiaojuan Su; Yi Qu; Long Ge; Yan Yue; Yan Zeng; Wenxing Li; Peng Hu; Dezhi Mu Journal: BMC Infect Dis Date: 2019-10-30 Impact factor: 3.090